137 related articles for article (PubMed ID: 11391580)
1. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
Jeung HC; Rha SY; Noh SH; Min JS; Kim BS; Chung HC
Cancer; 2001 Jun; 91(11):2016-25. PubMed ID: 11391580
[TBL] [Abstract][Full Text] [Related]
2. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
Atiq OT; Kelsen DP; Shiu MH; Saltz L; Tong W; Niedzwiecki D; Trochanowski B; Lin S; Toomasi F; Brennan M
J Clin Oncol; 1993 Mar; 11(3):425-33. PubMed ID: 8445416
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
Kollmannsberger C; Budach W; Stahl M; Schleucher N; Hehr T; Wilke H; Schleicher J; Vanhoefer U; Jehle EC; Oechsle K; Trarbach T; Boehlke I; Kanz L; Hartmann JT; Bokemeyer C
Ann Oncol; 2005 Aug; 16(8):1326-33. PubMed ID: 15919686
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Jeung HC; Moon YW; Rha SY; Yoo NC; Roh JK; Noh SH; Min JS; Kim BS; Chung HC
Ann Oncol; 2008 Mar; 19(3):520-6. PubMed ID: 18029971
[TBL] [Abstract][Full Text] [Related]
9. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
10. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
[TBL] [Abstract][Full Text] [Related]
11. The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute.
Yakir R; Luna K; Marc W; Tamar S; Avraham R; Ayala H
Ann Acad Med Singap; 2008 Mar; 37(3):200-4. PubMed ID: 18392298
[TBL] [Abstract][Full Text] [Related]
12. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
14. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
Leichman L; Silberman H; Leichman CG; Spears CP; Ray M; Muggia FM; Kiyabu M; Radin R; Laine L; Stain S
J Clin Oncol; 1992 Dec; 10(12):1933-42. PubMed ID: 1453207
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Macdonald JS; Fleming TR; Peterson RF; Berenberg JL; McClure S; Chapman RA; Eyre HJ; Solanki D; Cruz AB; Gagliano R
Ann Surg Oncol; 1995 Nov; 2(6):488-94. PubMed ID: 8591078
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
Arkenau HT; Rettig K; Porschen R
Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
[TBL] [Abstract][Full Text] [Related]
19. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
Chen S; Chen YB; Zhou ZW; Li W; Sun XW; Xu DZ; Li YF; Guan YX; Feng XY; Zhan YQ
Am J Clin Oncol; 2011 Jun; 34(3):309-13. PubMed ID: 20838324
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
Zhang XL; Shi HJ; Cui SZ; Tang YQ; Ba MC
Eur J Surg Oncol; 2011 Jun; 37(6):466-72. PubMed ID: 21414740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
